Table 2.
Response to VTD regimen in each group.
| Response (n, %) | After 8 cycles | ||
|---|---|---|---|
| VTD group (n = 30) | Improved VTD group (n = 30) | P value | |
| OR | 22 (73.3%) | 23 (76.7%) | 0.766 |
| CR | 4 (13.3%) | 3 (10%) | 0.688 |
| VGPR | 10 (33.3%) | 11 (36.7%) | 0.787 |
| PR | 8 (26.7%) | 9 (30%) | 0.774 |
| MR | 4 (13.3%) | 4 (13.3%) | 1.000 |
| SD | 3 (10%) | 3 (10%) | 1.000 |
| PD | 1 (3.3%) | 0 | 0.313 |
| Not evaluable | 0 | 0 | 1.000 |
OR (CR + VGPR + PR): overall response; CR: complete response; VGPR: very good partial response; PR: partial response; MR: minimal response; SD: stable disease; PD: progressive disease; VTD: bortezomib and thalidomide plus dexamethasone.